Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM1V5ZS)

Drug Name

Felbamate Drug Info

Synonyms

Felbamato; Felbamatum; Felbamyl; Felbatol; Taloxa; Essex brand of felbamate; Felbamato [Spanish]; Felbamatum [Latin]; Schering brand of felbamate; F 0778; W 554; Wallace brand 1 of felbamate; Wallace brand 2 of felbamate; ADD-03055; Carbamic acid 2-phenyltrimethylene ester; Felbamate [USAN:INN]; Felbatol (TN); Schering-Plough brand of felbamate; W-554; Carbamic acid, 2-phenyltrimethylene ester; Felbamate (USAN/INN); (3-carbamoyloxy-2-phenyl-propyl) carbamate; (3-carbamoyloxy-2-phenylpropyl) carbamate; 1,3-Propanediol, 2-phenyl-, dicarbamate; 2-Phenyl-1,3-propanediol dicarbamate; 2-Phenylpropane-1,3-diyl dicarbamate

Indication

Disease Entry	ICD 11	Status	REF
Epilepsy	8A60-8A68	Approved	[1]

Therapeutic Class

Antiepileptic Agents

Cross-matching ID

PubChem CID: 3331
ChEBI ID: CHEBI:4995
CAS Number: CAS 25451-15-4
TTD Drug ID: DM1V5ZS
INTEDE Drug ID: DR0684
ACDINA Drug ID: D00266

Molecule-Related Drug Atlas

Molecule Type:

DTT

DME

DOT

Drug Status:

Approved Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting N-methyl-D-aspartate receptor (NMDAR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
L-Glutamic Acid	DM4PUDW	Schizophrenia	6A20	Approved	[7]
Cycloserine	DMT1I52	Bacterial infection	1A00-1C4Z	Approved	[8]
Benzphetamine	DMIJATC	Obesity	5B81	Approved	[9]
Ketamine	DMT5HA4	Anaesthesia	9A78.6	Approved	[10]
Memantine	DMD9WSC	Alzheimer disease	8A20	Approved	[11]
Huperzine A	DMMAWLU	Alzheimer disease	8A20	Approved	[12]
Levorphanol	DMGS80V	Pain	MG30-MG3Z	Approved	[13]
Magnesium Sulfate	DMVEK07	Acute pain	MG31	Approved	[14]
Magnesium	DMU4ORS	Ischemic stroke	8B11.5Z	Approved	[15]
Orphenadrine	DMW542E	Parkinson disease	8A00.0	Approved	[16]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Metabolized By Cytochrome P450 3A4 (CYP3A4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[17]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[18]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[19]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[20]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[21]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[22]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[23]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[24]
Prasterone	DM67VKL	Chronic obstructive pulmonary disease	CA22	Approved	[18]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[25]
Eplerenone	DMF0NQR	Heart failure	BD10-BD13	Approved	[35]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[36]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[37]
Voriconazole	DMAOL2S	Aspergillosis	1F20	Approved	[38]
Proguanil	DMBL79I	Malaria	1F40-1F45	Approved	[39]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[39]
Loratadine	DMF3AN7	Allergy	4A80-4A85	Approved	[40]
Nelfinavir mesylate	DMFX6G8	N. A.	N. A.	Approved	[41]
Capsaicin	DMGMF6V	Back pain	ME84.Z	Approved	[42]
Axitinib	DMGVH6N	Renal cell carcinoma	2C90	Approved	[43]
------------------------------------------------------------------------------------


⏷ Show the Full List of 20 Drug(s)

Drug(s) Metabolized By Cytochrome P450 2E1 (CYP2E1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Folic Acid	DMEMBJC	Colorectal carcinoma		Approved	[26]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[27]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[28]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[29]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[30]
Oxaliplatin	DMQNWRD	Adenocarcinoma	2D40	Approved	[31]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[4]
Estrone	DM5T6US	Acne vulgaris	ED80	Approved	[32]
Propofol	DMB4OLE	Anaesthesia	9A78.6	Approved	[33]
Ethanol	DMDRQZU	Chronic pain	MG30	Approved	[34]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Affected By Liver carboxylesterase 1 (CES1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Irinotecan	DMP6SC2	Adenocarcinoma	2D40	Approved	[44]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[45]
Dextropropoxyphene	DM23HCX	Pain	MG30-MG3Z	Approved	[46]
Selenium	DM25CGV	N. A.	N. A.	Approved	[47]
Naloxone	DM3FXMA	Narcotic depression	6A7Z	Approved	[48]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[49]
Tacrine	DM51FY6	Alzheimer disease	8A20	Approved	[50]
Rifampicin	DM5DSFZ	Non-insulin dependent diabetes	5A11	Approved	[51]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[52]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[53]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Affected By Cytochrome P450 2C9 (CYP2C9)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[36]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[54]
Dapsone	DM4LT8A	Acne vulgaris	ED80	Approved	[39]
Voriconazole	DMAOL2S	Aspergillosis	1F20	Approved	[38]
Capsaicin	DMGMF6V	Back pain	ME84.Z	Approved	[55]
Zafirlukast	DMHNQOG	Asthma	CA23	Approved	[56]
Niclosamide	DMJAGXQ	Cestodes infection	1F70-1F76	Approved	[39]
Eicosapentaenoic acid/docosa-hexaenoic acid	DMMUCG4	Hypertriglyceridemia	5C80.1	Approved	[57]
Fluconazole	DMOWZ6B	Cryptococcal meningitis		Approved	[38]
Quinine	DMSWYF5	Malaria	1F40-1F45	Approved	[39]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Affected By Cytochrome P450 2C8 (CYP2C8)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[58]
Cyclophosphamide	DM4O2Z7	Advanced cancer	2A00-2F9Z	Approved	[59]
Lovastatin	DM9OZWQ	Arteriosclerosis	BD40	Approved	[58]
Ifosfamide	DMCT3I8	Adult central nervous system germ cell tumor		Approved	[59]
Sulfinpyrazone	DMEV954	Gout	FA25	Approved	[60]
Loratadine	DMF3AN7	Allergy	4A80-4A85	Approved	[58]
Zafirlukast	DMHNQOG	Asthma	CA23	Approved	[58]
Ethinyl Estradiol	DMODJ40	Acne vulgaris	ED80	Approved	[58]
Sorafenib	DMS8IFC	Adenocarcinoma	2D40	Approved	[61]
Dabrafenib	DMX6OE3	Melanoma	2C30	Approved	[62]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
N-methyl-D-aspartate receptor (NMDAR)	TT9IK2Z	NOUNIPROTAC	Antagonist	[2]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4)	DE4LYSA	CP3A4_HUMAN	Substrate	[3]
Cytochrome P450 2E1 (CYP2E1)	DEVDYN7	CP2E1_HUMAN	Substrate	[4]

------------------------------------------------------------------------------------

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Cytochrome P450 2C8 (CYP2C8)	OTHCWT42	CP2C8_HUMAN	Regulation of Drug Effects	[5]
Cytochrome P450 2C9 (CYP2C9)	OTGLBN29	CP2C9_HUMAN	Regulation of Drug Effects	[5]
Cytochrome P450 3A4 (CYP3A4)	OTQGYY83	CP3A4_HUMAN	Drug Response	[6]
Liver carboxylesterase 1 (CES1)	OT9L0LR8	EST1_HUMAN	Regulation of Drug Effects	[5]

------------------------------------------------------------------------------------

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5473).
2	Molecular determinants of the anticonvulsant felbamate binding site in the N-methyl-D-aspartate receptor. J Med Chem. 2008 Mar 27;51(6):1534-45.
3	A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother. 1998 May;32(5):554-63.
4	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
5	Assessment of metabolic activation of felbamate in chimeric mice with humanized liver in combination with in vitro metabolic assays. J Toxicol Sci. 2022;47(7):277-288. doi: 10.2131/jts.47.277.
6	ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
7	Altered expression of genes involved in GABAergic transmission and neuromodulation of granule cell activity in the cerebellum of schizophrenia pati... Am J Psychiatry. 2008 Dec;165(12):1594-603.
8	How many modes of action should an antibiotic have Curr Opin Pharmacol. 2008 Oct;8(5):564-73.
9	Amphetamine inhibits the N-methyl-D-aspartate receptor-mediated responses by directly interacting with the receptor/channel complex. J Pharmacol Exp Ther. 2002 Mar;300(3):1008-16.
10	Ketamine modulates theta and gamma oscillations. J Cogn Neurosci. 2010 Jul;22(7):1452-64.
11	The NMDA receptor antagonist memantine as a symptomatological and neuroprotective treatment for Alzheimer's disease: preclinical evidence. Int J Geriatr Psychiatry. 2003 Sep;18(Suppl 1):S23-32.
12	Progress report on new antiepileptic drugs: a summary of the Ninth Eilat Conference (EILAT IX). Epilepsy Res. 2009 Jan;83(1):1-43.
13	Neuroprotective agents for the treatment of acute ischemic stroke. Curr Neurol Neurosci Rep. 2003 Jan;3(1):9-20.
14	Magnesium sulfate diminishes the effects of amide local anesthetics in rat sciatic-nerve block. Reg Anesth Pain Med. 2007 Jul-Aug;32(4):288-95.
15	Emerging drugs for acute ischemic stroke. Expert Opin Emerg Drugs. 2009 Mar;14(1):33-42.
16	Involvement of voltage-gated sodium channels blockade in the analgesic effects of orphenadrine. Pain. 2009 Apr;142(3):225-35.
17	Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
18	Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
19	Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
20	Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
21	Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
22	Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
23	Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
24	The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
25	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
26	Chronic ethanol feeding and folate deficiency activate hepatic endoplasmic reticulum stress pathway in micropigs. Am J Physiol Gastrointest Liver Physiol. 2005 Jul;289(1):G54-63.
27	Cytochrome P450 2E1 null mice provide novel protection against cisplatin-induced nephrotoxicity and apoptosis. Kidney Int. 2003 May;63(5):1687-96.
28	Genotoxicity of tamoxifen, tamoxifen epoxide and toremifene in human lymphoblastoid cells containing human cytochrome P450s. Carcinogenesis. 1994 Jan;15(1):5-9.
29	Acetaminophen induced acute liver failure via oxidative stress and JNK activation: protective role of taurine by the suppression of cytochrome P450 2E1. Free Radic Res. 2010 Mar;44(3):340-55.
30	A study on the metabolism of etoposide and possible interactions with antitumor or supporting agents by human liver microsomes. J Pharmacol Exp Ther. 1998 Sep;286(3):1294-300.
31	The influence of metabolic gene polymorphisms on urinary 1-hydroxypyrene concentrations in Chinese coke oven workers. Sci Total Environ. 2007 Aug 1;381(1-3):38-46.
32	Novel metabolic pathway of estrone and 17beta-estradiol catalyzed by cytochrome P-450. Drug Metab Dispos. 2000 Feb;28(2):110-2.
33	Inhibition of cytochrome P450 2E1 by propofol in human and porcine liver microsomes. Biochem Pharmacol. 2002 Oct 1;64(7):1151-6.
34	CYP2E1 and clinical features in alcoholics. Neuropsychobiology. 2003;47(2):86-9.
35	The relative role of CYP3A4 and CYP3A5 in eplerenone metabolism. Toxicol Lett. 2019 Oct 15;315:9-13.
36	Characterization of the structural determinants required for potent mechanism-based inhibition of human cytochrome P450 1A1 by cannabidiol. Chem Biol Interact. 2014 May 25;215:62-8.
37	Retinoids activate the RXR/SXR-mediated pathway and induce the endogenous CYP3A4 activity in Huh7 human hepatoma cells. Toxicol Sci. 2006 Jul;92(1):51-60.
38	The novel azole R126638 is a selective inhibitor of ergosterol synthesis in Candida albicans, Trichophyton spp., and Microsporum canis. Antimicrob Agents Chemother. 2004 Sep;48(9):3272-8.
39	Application of higher throughput screening (HTS) inhibition assays to evaluate the interaction of antiparasitic drugs with cytochrome P450s. Drug Metab Dispos. 2001 Jan;29(1):30-5.
40	Cetirizine and loratadine-based antihistamines with 5-lipoxygenase inhibitory activity. Bioorg Med Chem Lett. 2004 Nov 15;14(22):5591-4.
41	Mechanism-based inactivation of CYP3A by HIV protease inhibitors. J Pharmacol Exp Ther. 2005 Feb;312(2):583-91.
42	Studies of the toxicological potential of capsinoids, XIII: inhibitory effects of capsaicin and capsinoids on cytochrome P450 3A4 in human liver microsomes. Int J Toxicol. 2010 Mar;29(2 Suppl):22S-6S.
43	Investigation of the effects of axitinib on the pharmacokinetics of loperamide and its main metabolite N-demethylated loperamide in rats by UPLC-MS/MS. Chem Biol Interact. 2019 Sep 1;310:108744. doi: 10.1016/j.cbi.2019.108744. Epub 2019 Jul 9.
44	Concise prediction models of anticancer efficacy of 8 drugs using expression data from 12 selected genes. Int J Cancer. 2004 Sep 10;111(4):617-26. doi: 10.1002/ijc.20289.
45	Cannabidiol Activates Neuronal Precursor Genes in Human Gingival Mesenchymal Stromal Cells. J Cell Biochem. 2017 Jun;118(6):1531-1546. doi: 10.1002/jcb.25815. Epub 2016 Dec 29.
46	Binding and hydrolysis of meperidine by human liver carboxylesterase hCE-1. J Pharmacol Exp Ther. 1999 Jul;290(1):314-8.
47	Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer. J Natl Cancer Inst. 2009 Mar 4;101(5):306-20.
48	Human carboxylesterase 1: from drug metabolism to drug discovery. Biochem Soc Trans. 2003 Jun;31(Pt 3):620-4. doi: 10.1042/bst0310620.
49	Transcriptional and Metabolic Dissection of ATRA-Induced Granulocytic Differentiation in NB4 Acute Promyelocytic Leukemia Cells. Cells. 2020 Nov 5;9(11):2423. doi: 10.3390/cells9112423.
50	Crystal structure of human carboxylesterase 1 complexed with the Alzheimer's drug tacrine: from binding promiscuity to selective inhibition. Chem Biol. 2003 Apr;10(4):341-9. doi: 10.1016/s1074-5521(03)00071-1.
51	Dexamethasone differentially regulates expression of carboxylesterase genes in humans and rats. Drug Metab Dispos. 2000 Feb;28(2):186-91.
52	Keratinocyte-derived IL-36gama plays a role in hydroquinone-induced chemical leukoderma through inhibition of melanogenesis in human epidermal melanocytes. Arch Toxicol. 2019 Aug;93(8):2307-2320.
53	Proteomics investigations of drug-induced hepatotoxicity in HepG2 cells. Toxicol Sci. 2011 Mar;120(1):109-22.
54	Comparative effects of thiazolidinediones on in vitro P450 enzyme induction and inhibition. Drug Metab Dispos. 2003 Apr;31(4):439-46.
55	Effects of capsaicin and dihydrocapsaicin on human and rat liver microsomal CYP450 enzyme activities in vitro and in vivo. J Asian Nat Prod Res. 2012;14(4):382-95.
56	Potential of pranlukast and zafirlukast in the inhibition of human liver cytochrome P450 enzymes. Xenobiotica. 2004 May;34(5):429-38.
57	The inhibitory effect of polyunsaturated fatty acids on human CYP enzymes. Life Sci. 2006 Nov 25;79(26):2432-40.
58	Examination of 209 drugs for inhibition of cytochrome P450 2C8. J Clin Pharmacol. 2005 Jan;45(1):68-78.
59	Identification of the polymorphically expressed CYP2C19 and the wild-type CYP2C9-ILE359 allele as low-Km catalysts of cyclophosphamide and ifosfamide activation. Pharmacogenetics. 1997 Jun;7(3):211-21.
60	Essential requirements for substrate binding affinity and selectivity toward human CYP2 family enzymes. Arch Biochem Biophys. 2003 Jan 1;409(1):32-44.
61	Differential inhibition of human CYP2C8 and molecular docking interactions elicited by sorafenib and its major N-oxide metabolite. Chem Biol Interact. 2021 Apr 1;338:109401. doi: 10.1016/j.cbi.2021.109401. Epub 2021 Feb 5.
62	Dabrafenib inhibits ABCG2 and cytochrome P450 isoenzymes; potential implications for combination anticancer therapy. Toxicol Appl Pharmacol. 2022 Jan 1;434:115797. doi: 10.1016/j.taap.2021.115797. Epub 2021 Nov 13.